EUVIMEDEUVIMED entdecken
Crossref

New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity

Aisha A Alsfouk iD, Hazem Elkady iD, Saber M Hassan, Walid E Elgammal iD, Hazem A Mahdy, Dalal Z Husein, Fatma G Amin, Mohamed Hagras iD, Eslam B Elkaeed, Ahmed M Metwaly iD, Ibrahim H Eissa iD

Chemical Biology & Drug Design · 2025-07 · 106 (1)

DOI: 10.1111/cbdd.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 20.07.2025. Verfasst von Aisha A Alsfouk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Thiadiazoles, Sulfonamides, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Princess Nourah Bint Abdulrahman University, AlMaarefa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new group of thiadiazole‐benzenesulfonamide hybrids was designed, synthesized, and biologically evaluated as potential dual inhibitors targeting B‐Raf and VEGFR‐2 for cancer therapy. The cytotoxic activity of the synthesized derivatives was assessed against HepG2 and Huh7 liver cancer cell lines, where compound 7a exhibited the most potent activity with IC 50 values of 17.89 μM and 25.07 μM, respectively. The kinase inhibition assay revealed that 7a strongly inhibited both B‐Raf (IC 50 = 0.11 μM) and VEGFR‐2 (IC 50 = 0.15 μM), surpassing sorafenib in B‐Raf inhibition. Further mechanistic studies revealed that 7a induced G2/M phase arrest, with a significant increase in late apoptotic cells (57.08%) compared to the control group (0.15%), confirming its pro‐apoptotic effect. The apoptotic pathway was further validated by caspase‐3 activation, Bax upregulation, and Bcl‐2 downregulation. Computational analyses verified the effective binding of compound 7a to VEGFR‐2. These analyses included molecular docking, molecular dynamic (MD) simulations, molecular mechanics with generalized Born and surface area solvation (MM‐GBSA), protein‐ligand interaction fingerprints (ProLIF), principal component analysis (PCAT), and free energy landscape (FEL) studies. Additionally, DFT studies indicated 7a 's stability and reactivity. In silico ADMET predictions indicated that the derivatives had good absorption, were non‐mutagenic, non‐carcinogenic, and exhibited low toxicity risks compared to sorafenib. These findings suggest that the synthesized thiadiazole‐benzenesulfonamide hybrids, particularly 7a , represent promising dual BRAF/VEGFR‐2 inhibitors with potent anti‐cancer activity, warranting further optimization and preclinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesSulfonamidesAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafHumansMolecular Docking SimulationApoptosisLiver NeoplasmsCell Line, TumorMolecular Dynamics SimulationHep G2 CellsCell ProliferationBenzenesulfonamides

Stichwörter der Autor:innen

B‐RafMD simulationsVEGFR‐2hepatocellular carcinomamolecular dockingthiadiazole‐benzenesulfonamide hybrids

Substanzen

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesSulfonamidesAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafKDR protein, humanBenzenesulfonamides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Chemistry, Faculty of Science, Al-Azhar University, Cairo, Egypt.
  • Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
  • Physics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
  • Department of Pharmaceutical Organic Chemistry, College of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Aisha A Alsfouk, Hazem Elkady, Walid E Elgammal, Mohamed Hagras, Ahmed M Metwaly, Ibrahim H Eissa

Förderung

  • Princess Nourah Bint Abdulrahman University
  • AlMaarefa University

Zitieren

APA

Alsfouk, A. A., Elkady, H., Hassan, S. M., Elgammal, W. E., Mahdy, H. A., Husein, D. Z., Amin, F. G., Hagras, M., Elkaeed, E. B., Metwaly, A. M., & Eissa, I. H. (2025). New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity. Chemical Biology & Drug Design, 106(1). https://doi.org/10.1111/cbdd.70156

Vancouver

Alsfouk AA, Elkady H, Hassan SM, Elgammal WE, Mahdy HA, Husein DZ, et al. New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity. Chemical Biology & Drug Design. 2025;106(1). doi:10.1111/cbdd.70156

BibTeX
@article{Alsfouk2025,
  author = {Alsfouk, Aisha A and Elkady, Hazem and Hassan, Saber M and Elgammal, Walid E and Mahdy, Hazem A and Husein, Dalal Z and Amin, Fatma G and Hagras, Mohamed and Elkaeed, Eslam B and Metwaly, Ahmed M and Eissa, Ibrahim H},
  title = {New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  volume = {106},
  number = {1},
  doi = {10.1111/cbdd.70156}
}
Kostenlos starten →